Production (Stage)
aTyr Pharma, Inc.
ATYR
$3.75
-$0.05-1.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 235.00K | 235.00K | 588.00K | 588.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 235.00K | 235.00K | 588.00K | 588.00K |
| Cost of Revenue | 52.82M | 54.37M | 54.90M | 50.41M | 46.28M |
| Gross Profit | -52.82M | -54.14M | -54.66M | -49.82M | -45.69M |
| SG&A Expenses | 14.23M | 13.78M | 13.39M | 12.70M | 13.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.05M | 68.15M | 68.29M | 63.11M | 59.36M |
| Operating Income | -67.05M | -67.91M | -68.05M | -62.53M | -58.77M |
| Income Before Tax | -63.42M | -64.02M | -63.82M | -57.90M | -53.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.42 | -64.02 | -63.82 | -57.90 | -53.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 4.00K | -1.00K | -1.00K | -1.00K | 3.00K |
| Net Income | -63.41M | -64.02M | -63.82M | -57.90M | -53.93M |
| EBIT | -67.05M | -67.91M | -68.05M | -62.53M | -58.77M |
| EBITDA | -66.35M | -67.21M | -67.35M | -61.82M | -58.08M |
| EPS Basic | -0.81 | -0.87 | -0.94 | -0.91 | -0.90 |
| Normalized Basic EPS | -0.50 | -0.54 | -0.59 | -0.57 | -0.56 |
| EPS Diluted | -0.81 | -0.87 | -0.94 | -0.91 | -0.90 |
| Normalized Diluted EPS | -0.50 | -0.54 | -0.59 | -0.57 | -0.56 |
| Average Basic Shares Outstanding | 317.30M | 296.89M | 273.43M | 255.51M | 238.37M |
| Average Diluted Shares Outstanding | 317.30M | 296.89M | 273.43M | 255.51M | 238.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |